The Night-Shift Cluster
Over eight weeks, four of the eleven night-shift workers in a plastics injection-moulding plant have attended the local emergency department with chest tightness and wheeze; two were treated for what was recorded as 'reactive airways dysfunction.' All four work on the same line and all started within the last 18 months. Day-shift workers on the same line report nothing similar. The plant has no formal incident-investigation procedure for ill health - only for injuries - and the last sickness-absence review was 14 months ago. The line runs a new release agent introduced about the time the first case appeared; the safety data sheet lists 'respiratory sensitization' as a hazard but gives no exposure limit. The production manager says the ED visits are 'coincidence and probably personal health' and that investigating would alarm the workforce.
1. Is this a reportable event and an incident requiring investigation? Justify your answer.
Read the worked answer
Reportability: likely yes, but confirm against the jurisdiction's specific list and thresholds. The pattern - multiple workers with similar respiratory symptoms, two with a diagnosis consistent with occupational asthma/RADS, a plausible new agent with a sensitization hazard, and a temporal and spatial cluster - meets the spirit of an occupational disease/ill-health report. Report through the correct channel; do not rely on the ED to do it.
Investigation: yes, and the absence of an ill-health investigation procedure is itself a finding. The trigger for investigation is not 'injury vs illness' - it is a cluster of adverse health outcomes with a plausible work-related cause. The production manager's 'coincidence' framing is an assertion, not an analysis, and 'alarm the workforce' is not a valid reason to not investigate; unexplained illness is more alarming than a visible, competent response.
What to investigate:
- Case definition and case-finding - are there milder cases that never reached the ED? Interview all line workers.
- Exposure characterization: the release agent, its constituents, application method, ventilation, and whether exposure limits exist (absence of a limit does not mean absence of hazard - apply a recognized assessment approach, e.g., benchmarking against analogous substances or a control-banding approach).
- Timing: compare introduction date, shift patterns, and task assignments against onset dates.
- Confounders: smoking, prior asthma, other exposures - but confounders explain, they don't dismiss.
Interim: reduce exposure now (substitution review, LEV, restricted access), not after the investigation concludes.
2. What does the 'respiratory sensitization' hazard and the missing exposure limit mean for your risk assessment and control decisions?
Read the worked answer
Sensitization changes the rules. For a sensitizer, the goal is not to keep exposure below a limit - it is to prevent sensitization from occurring at all, because once sensitized, very low exposures can trigger reactions and the worker may have to be removed permanently from the exposure. That means:
- No established limit ≠ no control obligation. The absence of a limit means you cannot rely on a numerical benchmark; you must use a structured approach - hazard banding/control banding, benchmarking against structurally similar substances, or a conservative 'as low as reasonably practicable' target. Document the reasoning.
- Substitution is the priority. Can the release agent be replaced with a non-sensitizing alternative? This is the highest-value control and should be evaluated first.
- Engineering controls - enclosure and local exhaust at the point of application, with verification that they work (not just that they exist).
- Health surveillance for the exposed group - a structured questionnaire and, where appropriate, spirometry, with a baseline for new starters and periodic review. This is how you catch cases before they become ED visits.
- Individual action: any worker with confirmed sensitization should be assessed by a physician for continued exposure; removal from exposure may be necessary and should be managed as a work-restriction process, not a disciplinary one.
- Record the uncertainty in the risk assessment and set a review date as new information arrives.
3. Draft the key messages you would give the production manager and the workforce, and explain how you would handle the confidentiality of the four affected workers.
Read the worked answer
To the production manager:
- The cluster is a legitimate OHS signal, not a coincidence to be explained away. Investigating is the lower-risk path: it protects workers, demonstrates due diligence, and limits liability.
- The business case: undetected sensitization can lead to permanent impairment, claims, and loss of experienced staff. Early control is cheaper than late harm.
- Set expectations: an investigation is not an accusation; it is a structured look at exposure, timing, and controls. Give him a timeline and his role (access, data, decisions on controls).
To the workforce:
- Be transparent about what is known and not known: a pattern of respiratory symptoms on the line is being investigated; the release agent is being reviewed; controls are being strengthened.
- Tell them what to do if they have symptoms (report to their supervisor or the health service; no penalty for reporting).
- Invite questions through the safety committee. Silence breeds rumour.
Confidentiality:
- The four workers' identities and clinical details stay in the medical record. The manager and the wider workforce get aggregate information only - 'four workers on the line have reported respiratory symptoms' - not names or diagnoses.
- Obtain consent before sharing any individual detail with a manager or a physician outside the program.
- If work restrictions are needed, communicate only the restriction (e.g., 'no exposure to the release agent pending review'), not the reason.
- Be clear with workers about who will see what and why, in advance.